Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Oncol. 2008 Oct 20;26(30):4940-3. doi: 10.1200/JCO.2007.15.6315. Epub 2008 Jul 7.

Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC.

Author information

  • 1Centre Hospitalier Universitaire (CHU) Hôtel-Dieu, Cellule de Promotion à la Recherche Clinique, CHU Hotel-Dieu, Nantes, France. patrice.chevallier@chu-nantes.fr

Abstract

PURPOSE:

This retrospective multicenter study assessed the outcome of 51 patients with myeloid sarcoma (MS) who underwent allogeneic hematopoietic stem-cell transplantation (alloHSCT).

PATIENTS AND METHODS:

Most patients had MS presenting in conjunction with acute myeloid leukemia (AML) or after AML. Six patients had isolated MS. The median time between diagnosis and alloHSCT was 8 months (range, 2.8 to 67). Forty patients were in complete remission (CR) at time of alloHSCT.

RESULTS:

With a median follow-up of 33 (range, 1 to 182) months, the Kaplan-Meier estimates of overall survival (OS) and disease-free survival were 47% (95% CI, 33% to 61%) and 36% (95% CI, 24% to 50%) at 5 years. Twenty patients (39%) relapsed at a median of 204 (range, 35 to 1151) days after alloHSCT, with relapse being the major cause of death. In a Cox multivariate analysis, age > or = 15 years and remission status at time of alloHSCT (CR v other) were associated with improved OS (hazard ratio [HR], 0.27; 95% CI, 0.12 to 0.65; P = .003; and HR, 0.22; 95% CI, 0.08 to 0.57; P = .002, respectively).

CONCLUSION:

We conclude that first-line alloHSCT performed early in the course of MS is a valid therapeutic option.

[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk